What is Invion?
Invion operates at the intersection of advanced medical research and therapeutic innovation, specifically focusing on the transformation of Photodynamic Therapy (PDT) for the treatment of various cancers. By leveraging its proprietary Photosoft technology, the company is positioned as a key player in the development of novel, non-invasive treatment modalities. Listed on the Australian Securities Exchange (ASX:IVX), Invion maintains a robust intellectual property portfolio, holding exclusive license and distribution rights across the Asia-Pacific region and North America. Its operational model is bolstered by strategic research and development service agreements, ensuring a disciplined approach to clinical trial execution and regulatory milestones.
How much funding has Invion raised?
Invion has raised a total of $2M across 1 funding round:
Share Placement
$2M
Share Placement (2025): $2M, investors not publicly disclosed
Key Investors in Invion
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Invion?
With the recent influx of capital, Invion is well-positioned to accelerate its clinical trial pipeline and deepen its research into the efficacy of Photosoft technology. The company's strategic roadmap likely involves scaling its R&D capabilities to meet the rigorous demands of international regulatory bodies, thereby enhancing its market presence in the global oncology sector. By prioritizing the advancement of its core therapeutic assets, Invion aims to transition from a research-focused entity to a commercial-stage leader in PDT, ultimately seeking to improve patient outcomes through precision-based medical interventions. Future growth will be contingent upon the successful navigation of clinical data readouts and the continued support of its strategic partners.
See full Invion company page
